rs869069617
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_001406993.1(LMNA):c.-110C>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: not found (cov: 32)
Consequence
LMNA
NM_001406993.1 5_prime_UTR_premature_start_codon_gain
NM_001406993.1 5_prime_UTR_premature_start_codon_gain
Scores
13
5
2
Clinical Significance
Conservation
PhyloP100: 7.91
Genes affected
LMNA (HGNC:6636): (lamin A/C) The protein encoded by this gene is part of the nuclear lamina, a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.875
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LMNA | NM_170707.4 | c.449C>T | p.Thr150Ile | missense_variant | 2/12 | ENST00000368300.9 | NP_733821.1 | |
LMNA | NM_005572.4 | c.449C>T | p.Thr150Ile | missense_variant | 2/10 | ENST00000677389.1 | NP_005563.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LMNA | ENST00000368300.9 | c.449C>T | p.Thr150Ile | missense_variant | 2/12 | 1 | NM_170707.4 | ENSP00000357283.4 | ||
LMNA | ENST00000677389.1 | c.449C>T | p.Thr150Ile | missense_variant | 2/10 | NM_005572.4 | ENSP00000503633.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Cardiomyopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | May 16, 2023 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 09, 2015 | Variant classified as Uncertain Significance - Favor Pathogenic. The p.Thr150Ile variant in LMNA has been previously reported in 1 individual with DCM (Hirtle-L ewis 2013) and was absent from large population studies. In addition, another di sease-causing variant at this position (p.Thr150Pro) has been reported in 2 indi viduals with Emery-Dreifuss muscular dystrophy with conduction system disease (F elice 2000, Schamer 2011) and was identified by our laboratory in 4 family membe rs with clinical features of LMNA-related cardiomyopathy (DCM, muscle weakness, and/or conduction system disease; LMM unpublished data), suggesting that a chang e at this position may not be tolerated. Computational prediction tools and cons ervation analysis suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, whi le there is some suspicion for a pathogenic role, the clinical significance of t he p.Thr150Ile variant is uncertain. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 01, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Reported in individuals with dilated cardiomyopathy (Hirtle-Lewis et al., 2013; Chami et al., 2014); This variant is associated with the following publications: (PMID: 24037902, 1300868, 30402260, 25448463, 10939567, 20848652, 10908904) - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 18, 2024 | The p.T150I variant (also known as c.449C>T), located in coding exon 2 of the LMNA gene, results from a C to T substitution at nucleotide position 449. The threonine at codon 150 is replaced by isoleucine, an amino acid with similar properties. This variant has been detected in individuals from dilated cardiomyopathy cohorts (Hirtle-Lewis M et al. Clin Cardiol, 2013 Oct;36:628-33; Chami N et al. Can J Cardiol, 2014 Dec;30:1655-61; Adler A et al. Circ Arrhythm Electrophysiol, 2016 Jan;9:e003440; Mazzarotto F et al. Circulation, 2020 Feb;141:387-398). Another alteration at the same codon, p.T150P (c.448A>C), has been reported in association with phenotypes consistent with laminopathies (Felice KJ. Neurology. 2000 Jul;55(2):275-80). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
CardioboostCm
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
.;.;.;D;.;.;.;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
H;.;H;H;H;.;.;.;.
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;D;D;D;D;D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D;D;D;D;D;D
Sift4G
Benign
T;T;T;T;T;T;T;D;T
Polyphen
P;.;D;P;.;.;D;.;.
Vest4
MutPred
Loss of phosphorylation at T150 (P = 0.0398);Loss of phosphorylation at T150 (P = 0.0398);Loss of phosphorylation at T150 (P = 0.0398);Loss of phosphorylation at T150 (P = 0.0398);Loss of phosphorylation at T150 (P = 0.0398);.;.;.;.;
MVP
MPC
2.2
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at